Selection of Patients with <i>Staphylococcus aureus</i> Bloodstream Infection for Final Analysis.

<p>Abbreviations: BSI, bloodstream infection; MELD, Model for End-stage Liver Disease. Sixty-one patients were excluded due to missing medication data on vitamin K antagonists and novel oral anticoagulants.</p

Selection of Patients with <i>Staphylococcus aureus</i> Bloodstream Infection for Final Analysis.

<p>Abbreviations: BSI, bloodstream infection; MELD, Model for End-stage Liver Disease. Sixty-one patients were excluded due to missing medication data on vitamin K antagonists and novel oral anticoagulants.</p

Predictors of 30-Day All-Cause Mortality in Patients with <i>Staphylococcus aureus</i> Bloodstream Infection (n <i>=</i> 561); Univariable and Multivariable Analyses.

<p>Predictors of 30-Day All-Cause Mortality in Patients with <i>Staphylococcus aureus</i> Bloodstream Infection (n <i>=</i> 561); Univariable and Multivariable Analyses.</p

Demographic, Laboratory and Infection Characteristics of Patients with a <i>Staphylococcus aureus</i> Bloodstream Infection (n = 561).

<p>Demographic, Laboratory and Infection Characteristics of Patients with a <i>Staphylococcus aureus</i> Bloodstream Infection (n = 561).</p

The Model for End-stage Liver Disease (MELD) as a predictor of short-term mortality in <i>Staphylococcus aureus</i> bloodstream infection: A single-centre observational study

<div><p>Background</p><p>Automated laboratory-based prediction models may support clinical decisions in <i>Staphylococcus aureus</i> bloodstream infections (BSIs), which carry a particularly high mortality. Small studies indicated that the laboratory-based Model for End-stage Liver Disease (MELD) score is a risk factor for mortality in critically ill patients with infections. For <i>S</i>. <i>aureus</i> BSIs, we therefore aimed to assess a potential association of the MELD score with mortality.</p><p>Methods</p><p>In this single-centre observational study, all consecutive patients with a first episode of methicillin-susceptible <i>S</i>. <i>aureus</i> BSI occurring between 2001 and 2013 were eligible. Relevant patient data were retrieved from our prospective in-house BSI database. We assessed the association of the MELD score at day of BSI onset (range ± two days) with 30-day all-cause mortality using uni- and multivariable logistic regression analysis.</p><p>Results</p><p>561 patients were included in the final analysis. The MELD score at BSI onset was associated with 30-day mortality in <i>S</i>. <i>aureus</i> BSIs (odds ratio per 1-point increase, 1.06; 95% confidence interval, 1.03‒1.09; <i>P</i> < 0.001). After adjustment for relevant patient and infection characteristics, an increased MELD score remained a predictor of 30-day mortality (adjusted odds ratio per 1-point increase, 1.05; 95% confidence interval, 1.01‒1.08; <i>P</i> = 0.005).</p><p>Conclusions</p><p>In our study population, the MELD score at BSI onset was an independent predictor of mortality in <i>S</i>. <i>aureus</i> BSIs. We therefore suggest to prospectively validate the MELD score as part of clinical decision support systems in inpatients with suspected or confirmed BSI.</p></div

30-Day All-Cause Mortality in Patients with <i>Staphylococcus aureus</i> Bloodstream Infection Stratified by the MELD Score Category at Bloodstream Infection Onset (n = 561).

<p>30-Day All-Cause Mortality in Patients with <i>Staphylococcus aureus</i> Bloodstream Infection Stratified by the MELD Score Category at Bloodstream Infection Onset (n = 561).</p